David P Kodack
Overview
Explore the profile of David P Kodack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1369
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chapeau E, Sansregret L, Galli G, Chene P, Wartmann M, Mourikis T, et al.
Nat Cancer
. 2024 Jun;
5(7):1130.
PMID: 38886525
No abstract available.
2.
Chapeau E, Sansregret L, Galli G, Chene P, Wartmann M, Mourikis T, et al.
Nat Cancer
. 2024 Apr;
5(7):1102-1120.
PMID: 38565920
The YAP-TEAD protein-protein interaction mediates YAP oncogenic functions downstream of the Hippo pathway. To date, available YAP-TEAD pharmacologic agents bind into the lipid pocket of TEAD, targeting the interaction indirectly...
3.
Ferraro G, Ali A, Luengo A, Kodack D, Deik A, Abbott K, et al.
Nat Cancer
. 2022 Feb;
2(11):1243.
PMID: 35122065
No abstract available.
4.
Hu H, Piotrowska Z, Hare P, Chen H, Mulvey H, Mayfield A, et al.
Cancer Cell
. 2021 Oct;
39(11):1531-1547.e10.
PMID: 34624218
Cancer-associated fibroblasts (CAFs) are highly heterogeneous. With the lack of a comprehensive understanding of CAFs' functional distinctions, it remains unclear how cancer treatments could be personalized based on CAFs in...
5.
Ferraro G, Ali A, Luengo A, Kodack D, Deik A, Abbott K, et al.
Nat Cancer
. 2021 Jun;
2(4):414-428.
PMID: 34179825
Brain metastases are refractory to therapies that control systemic disease in patients with human epidermal growth factor receptor 2 (HER2+) breast cancer, and the brain microenvironment contributes to this therapy...
6.
Askoxylakis V, Ferraro G, Badeaux M, Kodack D, Kirst I, Shankaraiah R, et al.
NPJ Breast Cancer
. 2019 Jan;
5:4.
PMID: 30675514
The effective treatment of cerebral metastases from HER2-positive breast cancer remains an unmet need. Recent studies indicate that activated astrocytes and brain endothelial cells exert chemoprotective effects on cancer cells...
7.
Kodack D, Farago A, Dastur A, Held M, Dardaei L, Friboulet L, et al.
Cell Rep
. 2017 Dec;
21(11):3298-3309.
PMID: 29241554
Personalized cancer therapy is based on a patient's tumor lineage, histopathology, expression analyses, and/or tumor DNA or RNA analysis. Here, we aim to develop an in vitro functional assay of...
8.
Askoxylakis V, Kodack D, Ferraro G, Jain R
Breast Cancer Res Treat
. 2017 Jun;
165(2):467-468.
PMID: 28643019
No abstract available.
9.
Kodack D, Askoxylakis V, Ferraro G, Sheng Q, Badeaux M, Goel S, et al.
Sci Transl Med
. 2017 May;
9(391).
PMID: 28539475
Although targeted therapies are often effective systemically, they fail to adequately control brain metastases. In preclinical models of breast cancer that faithfully recapitulate the disparate clinical responses in these microenvironments,...
10.
Ferraro G, Kodack D, Askoxylakis V, Jain R
Cell Res
. 2016 Aug;
26(9):973-4.
PMID: 27514701
Astrocytes are emerging as essential regulators of brain metastasis progression. In a current issue of Nature, Chen et al. identify a novel mechanism of astrocyte-carcinoma interaction and exploit vulnerabilities therein...